Literature DB >> 3390343

Late toxicity of radiotherapy in Hodgkin's disease. The role of fraction size.

J M Cosset1, M Henry-Amar, T Girinski, E Malaise, N Dupouy, J Dutreix.   

Abstract

From 1972 to 1976 patients at the Gustave Roussy Institute were irradiated for Hodgkin's disease using a modified fractionation schedule (3 fractions of 3.3 Gy per week) for operational reasons. From 1964 to 1971 and from 1977 to 1981, a more conventional regimen (4 fractions of 2.5 Gy per week) was used. The rates of the late complications in these two subsets of patients treated with different fractionation schedules at the same total dose of 40 Gy during the same overall time were compared. Mediastinitis was observed in 19% of the '4 X 2.5 Gy/week' group versus 56% in the '3 X 3.3 Gy/week' group. Pericarditis in 0% versus 9%, gastroduodenal ulceration and severe gastritis in 10 versus 21% and small bowel obstruction in 5 versus 8%. When using the linear quadratic model with an alpha/beta of 2.5 Gy to evaluate the equivalent dose of 40 Gy given in 12 fractions of 3.3 Gy when delivered by fractions of 2.5 Gy, a value of 46.6 Gy is found. This difference of 6.6 Gy in the equivalent doses (for late toxicity) is likely to account for the significant increase of late radiation injuries, such as mediastinitis and pericarditis, in the present study. The local relapse rate was found to be slightly lower in the 3 X 3.3 Gy group. However, this possible benefit cannot offset the considerable increase of late complications.

Entities:  

Mesh:

Year:  1988        PMID: 3390343     DOI: 10.3109/02841868809090332

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.

Authors:  Amode R Tembhekar; Cari L Wright; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2016-12-22       Impact factor: 4.785

2.  Effect of accurate heart delineation on cardiac dose during the CONVERT trial.

Authors:  Nicki Groom; Elena Wilson; Corinne Faivre-Finn
Journal:  Br J Radiol       Date:  2017-03-31       Impact factor: 3.039

Review 3.  Post-operative radiation therapy.

Authors:  Amaury Paumier; Cécile Le Péchoux
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Robert T Dess; Yilun Sun; Martha M Matuszak; Grace Sun; Payal D Soni; Latifa Bazzi; Venkatesh L Murthy; Jason W D Hearn; Feng-Ming Kong; Gregory P Kalemkerian; James A Hayman; Randall K Ten Haken; Theodore S Lawrence; Matthew J Schipper; Shruti Jolly
Journal:  J Clin Oncol       Date:  2017-03-16       Impact factor: 44.544

5.  Late cardiopulmonary toxicity after treatment for Hodgkin's disease.

Authors:  C Allavena; T Conroy; P Aletti; P Bey; P Lederlin
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

6.  Association of lung and heart dose with survival in patients with non-small cell lung cancer underwent volumetric modulated arc therapy.

Authors:  Lanxiao Shen; Cong Liu; Juebin Jin; Ce Han; Yongqiang Zhou; Xiaomin Zheng; Changfei Gong; Mengfeng Chen; Congying Xie; Xiance Jin
Journal:  Cancer Manag Res       Date:  2019-07-03       Impact factor: 3.989

7.  A case report evaluating combined effect of intensity-modulated radiotherapy and deep inspiratory breath-hold for mediastinal lymphoma: A dosimetric analysis.

Authors:  Abhinav Dewan; Kundan Singh Chufal; Sarthak Tandon; Irfan Ahmad; T Suresh; Ajay Dewan; Anjali Pahuja
Journal:  Lung India       Date:  2020 Jan-Feb
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.